Quantcast

Latest treatment of bipolar disorder Stories

2014-05-15 23:02:33

Comprehensive research report “Omega-3 Polyunsaturated Fatty Acids (PUFAs) - A Global Market Overview” elaborated by Industry Experts is available at MarketPublishers.com. According to the study, the overall omega-3 PUFAs consumption is anticipated to climb to USD 4.96 billion in value terms. London, UK (PRWEB) May 15, 2014 In 2013, the global consumption of omega-3 polyunsaturated fatty acids (PUFAs) stood at about 123,800 tonnes and was evaluated at nearly USD 2.3 billion. As of...

2014-05-14 20:23:53

WOODBRIDGE, ON, May 14, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF)(CSE:PVO) ("Pivotal" or "the Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, today announced changes to its Board designed to increase its independence and enhance Pivotal's corporate governance at this stage of the Company's development. Dr. Jackowski has stepped down as Chairman of Pivotal Therapeutics Inc. effective May...

2014-05-14 08:24:42

ALBANY, New York, May 14, 2014 /PRNewswire/ -- According to a new report published by Transparency Market Research "Melatonin Market for Food & Beverages, Dietary Supplements, Medicine and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019", the global demand for the phenolic resins was valued at USD 504 million in 2012 and is expected to reach USD 1,300.0 million in 2019, growing at a CAGR of 14.7% between 2013 and 2019....

2014-05-13 16:27:44

WOODBRIDGE, ON, May 13, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced that it has engaged Brandkarma LLC., an award winning, US-based, healthcare marketing and brand specialist with global expertise to support the Company's commercialization strategy for VASCAZEN(®). "VASCAZEN(®) represents a much-needed solution for...

2014-05-12 23:03:38

Therapist Researcher Al R Zia of Ann Arbor, MI produced amazing results in his first batch of clinical trials with Parkinson's Disease ended May 1st, 2014 via CranioSacral Integrative therapy. Documented & Logged Research data results shows the symptoms reversal by 31%. Extraordinary achievement. Ann Arbor, MI (PRWEB) May 12, 2014 Extraordinary results in the world we live in, is more of science fiction rather than real Science. Until we focus ourselves on the reversal of symptoms...

2014-05-12 08:28:11

BOSTON, May 12, 2014 /PRNewswire/ -- Verde Media Group Inc. (OTC:VMGI) and its Biotech Division ("VMBD") announces that Butazyme, LLC, "BTZ" a wholly owned company of VMBD, has broken ground and commenced construction of the omega-3 project site in Asia. The joint venture with Phoenix Energy "PXE" is fully financed and involves scaling and co-developing the BTZ omega-3 technology to 20,000 liters in phase-I. BTZ has developed a proprietary microbial technology to produce high value...

2014-05-07 23:11:26

Dr. Robert Moss discusses the Clinical Biopsychology Model as a brain-based psychotherapy approach from its origin to its current status. It represents a major step toward true psychotherapy integration. Greenville, SC (PRWEB) May 07, 2014 Clinical neuropsychologist Robert A. Moss, Ph.D., FACPN, FAACP discussed the origin and current status of his work on the columnar brain code model (Dimensional Systems Model) and its applied treatment approach (Clinical Biopsychology). He has discussed...

2014-05-07 12:30:30

WOODBRIDGE, ON, May 7, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent Number 8,715,648 titled "Formulations Comprising Omega-3 Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight in Cardiovascular Disease Patients (CVD) and Diabetics"....

2014-05-06 16:32:06

Companion health economics analysis shows Transcranial Magnetic Stimulation (TMS) is cost-effective among patients who fail to benefit from prior antidepressant medication NEW YORK, May 6, 2014 /PRNewswire/ -- Neuronetics, Inc. announced today a new analysis of data at the annual meeting of the American Psychiatric Association that shows Transcranial Magnetic Stimulation (TMS) administered with the NeuroStar TMS Therapy System resulted in greater symptom improvement than next-choice...

2014-05-06 16:31:55

WOODBRIDGE, ON, May 6, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it presented two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions held in Toronto, Ontario, Canada, May 1-3, 2014. Both posters discussed Omega-3 deficiency (OM3D)...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related